Table 3 Demographic and clinical characteristics at baseline
| Â | G1m phenotype | ||
|---|---|---|---|
| Â | 3,3 | 3,17 | 17,17 |
| Â | n = 120 | n = 98 | n = 32 |
Demographics | Â | Â | Â |
Age, years | 53 ± 14 | 53 ± 12* | 48 ± 12* |
Female, no. (%) | 95 (79) | 74 (76) | 28 (88) |
DMARD therapy | Â | Â | Â |
Prior DMARDs (no.) | 3.5 ± 1.6 | 3.4 ± 1.7 | 3.3 ± 1.6 |
Methotrexate use, no. (%) | 95 (79) | 81 (83) | 23 (72) |
Methotrexate dose (mg/wk) | 21 (15 to 25) | 25 (15 to 25) | 25 (17.5 to 25) |
Prednisone use, no. (%) | 39 (33) | 31 (32) | 12 (38) |
Prednisone dose (mg/day) | 7.5 (5 to 10) | 5 (5 to 7.5) | 10 (5 to 10) |
Disease status | Â | Â | Â |
Disease duration (years) | 10 (4 to 17) | 11 (3 to 16) | 7 (3 to 17) |
Rheumatoid factor positive, no. (%) | 80 (67)* | 70 (71) | 29 (91)* |
Erosive disease, no. (%) | 90 (75) | 76 (78) | 28 (88) |
Erythrocyte sedimentation rate (mm/h) | 29 ± 23 | 31 ± 25 | 28 ± 17 |
C-reactive protein (mg/dl) | 11 (4 to 24) | 10 (6 to 23) | 14 (6 to 31) |
DAS28 | 5.1 ± 1.2 | 5.3 ± 1.2 | 5.2 ± 1.0 |